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MICROBE DETECTION VIA HYBRIDIZING
MAGNETIC RELAXATION NANOSENSORS

changes in the sample's magnetic resonance signal (specifically the water proton relaxation time; T2) occur that correlate with the target concentration in solution. By measuring
the changes in T2 relaxation times upon target interaction and
correlating the intensity of the change with the target concentration, one can develop a sensitive detection method, therefore the acronym of magnetic relaxation nano sensors (MRS).
In contrast to other methods that utilize magnetic nanoparticles as labels and directly measure an intrinsic physical
property, such as a magnetic field [13], [14], or a chemical
property [6], the MRS method relies on the effect that the
nanoparticle' s induced magnetic field exerts on the hundreds
of thousands of water molecules surrounding the nanoparticle. This effect results in an amplification of the signal,
allowing for sensitive detection even in turbid and minimally
processed samples, without the need of further amplification,
which is critical for assays such as PCR and ELISA. Hence,
MRS-based assays can be more affordable than traditional
assays, since they use a single reagent that can be easily
produced in large quantities, and a single-step that avoids
time- and labor-consuming procedures. Additionally, MRS
can detect their targets at various point-of-care settings, since
the nanosensors are stable at ambient conditions and utilize
deployable instrumentation. Recently reported is a unique
MRS nanoparticle-target interaction that resulted in rapid T2
increases upon target binding [12]. This unique nanoparticletarget interaction is different from other MRS-based methods, because clustering of the nanoparticles is not required to
achieve detection. In contrast, binding of MRS to the target
caused fast, target-concentration-dependent increases in T2.
Kinetic studies also revealed that the binding of MRS was
faster and more sensitive than the MRS clustering, while
achieving lower detection thresholds. In addition, nanoparticle valency-the amount of a targeting ligand on the surface
of the nanoparticle-plays a role in the magnetic relaxation
response. Nanoparticle valency controls the trend of the
change in the spin-spin relaxation time (flT2). Specifically, it
has been found that low valency results in decreases in the
fl T2 as the target concentration increases, while at high
valency conditions the fl T2 increases as the target concentration increases.

The Sequence Listing submitted on Nov. 20, 2014 as a text
file named "26150_0051 U2_Sequence_Listing.txt," created
on Nov. 20, 2014, and having a size of741 bytes is hereby
incorporated by reference pursuant to 37 C.F.R. §1.52(e )(5).
BACKGROUND
10

Pathogenesis caused by intracellular pathogens, such as
Mycobacterium tuberculosis among others, relies on the survival of the microorganism within host cells, such as macrophages and dendritic cells. This mode of infection with or
without clinical symptomology hampers bacterial detection,
preventing correct diagnosis. Consequently, the physician
cannot proceed to the assignment of an appropriate treatment
course, delaying the clearance of the pathogen from the body.
Serological immunoassays cannot effectively detect intracellular pathogens in biological fluids (e.g. blood, lymphatic
fluid) as the microorganism is hidden away within the
immune cells. For this reason, isolation of the infected cells
and extraction of their DNA, followed by detection of specific
bacterial genomic markers via Polymerase Chain Reaction
(PCR), is needed to facilitate identification of the pathogen.
Although highly specific and sensitive, PCR methods are
generally laborious, time-consuming and typically require
homogeneous and pure DNA samples [1]. Evidently, complex biological samples, such as biopsies and blood, have to
be thoroughly processed in multistep elaborate protocols to
obtain pure DNA samples, significantly increasing the final
readout time, and affecting the overall DNA yield. An alternative way to detect intracellular pathogens, particularly
when they are in low numbers, is by isolating the infected
leukocytes from the blood and expanding the number of
viable bacteria via culturing methods before PCR analysis.
Although very effective, bacterial culturing methods require a
significant amount of time, such as in the case of slow-growing intracellular pathogens that have to be cultivated for even
weeks, assuming that there is an adequate amount of viable
pathogens in the clinical sample. Another drawback of culturing methods is that some pathogens do not grow effectively
in culture, either because of the nature of the pathogen itself
or the presence of biological interferences present in the
clinical sample that prevent growth in culture. Because of
these hurdles, new technologies that can detect the presence
of a pathogen in human clinical samples are urgently needed.
It has been predicted that nanotechnology will have a major
impact in medicine, agriculture and biotechnology among
other fields [2], [3], [4], [5], [6], [7], [8], [9], [10]. Innovative
technologies that take advantage of the unique size-dependent electronic, magnetic and luminescence properties that
some nanomaterials exhibit when they specifically interact
with a biological marker have been developed for faster and
more accurate sensing of various pathogens [2], [3], [4], [5].
However, the translation of these technologies to the clinical
diagnosis of an infectious disease and how it relates to the
presence of the pathogen in clinical samples has been limited.
The slow clinical translation of some of these nanotechnologies has been partly due to their poor performance in crude or
minimally processed clinical samples. Among the most
promising nanomaterials are magnetic relaxation nanosensors (MRS). These magnetic nanosensors are composed of a
polymer-coated iron oxide nanoparticle onto which affinity
ligands are conjugated to facilitate binding and magnetic
detection of a particular target [11], [12]. Upon specific binding of a target to ligands on the magnetic nanoparticle,
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Disclosed herein are materials and methods that take into
consideration the faster detection kinetics of MRS bindingbased detection assays and the higher sensitivity of the MRS
low-valency nanoparticle system. In one embodiment, disclosed is a newly developed nanosensor, hybridizing MRS
(hMRS), that switches (increases) the sample's water proton
relaxation times (T2) upon binding to a unique genomic
marker (e.g. microbial). According to one example, the
hMRSs were designed to bind to a specific genomic marker in
Mycobacterium avium spp. paratuberculosis (MAP); an
intracellular pathogen known to cause Johne's disease in
cattle [15] and has been also implicated in the cause of
Crohn's disease in humans [16]. Furthermore, acknowledging the limitations of PCR in detecting nucleic acid biomarkers of intracellular pathogens in clinical samples, the hMRS
performance in detecting MAP was examined in human
peripheral blood samples of Crohn' s disease patients as well
as animal tissues with Johne's disease.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or
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testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are
incorporated by reference in their entirety. In case of conflict,
the present specification, including definitions, will control.
In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

FIG. 6 (a) Blood samples from a second population (Cohort 2, n=26) were screened for the presence of the MAP
IS900 genomic element with hMRS, direct nPCR and culture-based nPCR after 12-week cultivation. The receiver
operating characteristic (ROC) curve indicated that the
hMRS, can better differentiate between symptomatic
(Crohn's) and asymptomatic (healthy) states than the two
gold standard methods. (b) Two-proportion z-test confirmed
hMRS as a better clinical diagnostic utility than the PCRbased methods.
FIG. 7 Kinetics for MAP's IS900 genomic marker detection with hMRS. After heating the samples to facilitate DNA
stand separation and hMRS hybridization, the changes in the
T 2 magnetic resonance signal were recorded over time, with
marked changes occurring within less than an hour
(Means± SE).
FIG. 8 Nested PCR (nPCR) cannot quantify crude MAP
DNA. -Ctr!: negative control (dH20) of the first nPCR
round, -Ctr!: negative control (dH20) of the second nPCR
round, TE: TE buffer, +Ctr!: two controls of pure extracted
MAP DNA.
FIG. 9 Genome-copy-based quantification of MAP with
hMRS and crude extracted DNA. Samples with known
amounts of crude DNA from cultured MAP were utilized to
correlate the changes in the T2 signal (fl T2+) and the number
of bacteria originally present in the sample, using the MAP' s
genome size as a reference. (Means±SE. SE too small to
depict in high bacterial levels.)

5

BRIEF DESCRIPTION OF DRAWINGS
10

FIG. 1 Design of a nanoparticle-based assay for the identification of genomic markers of the intracellular pathogen
Mycobacterium avium spp. paratuberculosis (MAP). (a) Isolation of MAP requires collection of infected white bloods
cells from blood samples via centrifugation. For direct nPCR
analysis, DNA directly isolated from white blood cells is
purified in multiple steps prior to amplification and detection
by gel electrophoresis. Meanwhile, culture-based nPCR
requires the growth of MAP in specialized liquid media for 12
weeks, followed by DNA isolation before nPCR. Hybridizing
magnetic relaxation sensors (hMRS) can detect MAP DNA in
minimally processed blood samples via changes in magnetic
signal (fl T2) in 1 hour, as opposed to 24 hours for direct nPCR
and 12 weeks for culture nPCR. (b) Preparation of MAP DNA
for hMRS. Heating ofinfected leucocytes facilities rupture of
the cell membrane releasing MAP DNA. Further heating and
cooling steps facilitates the annealing and binding of a MAP
specific hMRS, resulting in an increase in the T 2 water relaxation time.
FIG. 2 Specificity and sensitivity of the IS900-detecting
hMRS. (a) hMRS specifically bind to MAP DNA and not
DNA from other mycobacteria or common pathogens
([hMRS]=3 µg Fe/µL). hMRS facilitates the fast and quantitative detection of MAP DNA in pure (b) and crude (c)
samples within 30 minutes. Comparison of the sensitivity of
the hMRS and nested PCR (nPCR). (d) Within 30 minutes,
the hMRS detected a single MAP genome copy, translating to
one bacterium. (e) After its second amplification round (6
hours), nPCR achieved comparable sensitivity. (Upper gel
image: first nPCR round (3 hours), lower gel image: second
nPCRround (total two-round time 6 hours), -Ctr!: dH 2 0 and
0: sterile TE buffer).
FIG. 3 Screening of clinical isolates with hMRS and nPCR.
Comparison between the magnetic relaxation-mediated
detection of MAP in clinical isolates using hMRS after crude
DNA extraction and culture-based nPCR. All isolates were
from blood samples from Crohn' s disease patients, apart from
GN2' and GNS' that correspond to ilea! biopsies.
FIG. 4 Comparison between the hMRS genomic detection
of MAP in clinical isolates and homogenized tissues with the
presence of MAP protein markers using anti-MAP antibodies
conjugated MRS. (a) hMRS detected MAP genomic tags in
clinical isolates via changes in the magnetic resonance signal.
(b) A second preparation of magnetic nano sensors carrying
polyclonal anti-MAP antibodies (anti-MAP-pAb) was able to
corroborate the presence of MAP in these clinical isolates by
the identification of MAP surface epitopes. (c) hMRS
detected MAP's IS900 in homogenized tissue from Johne's
disease cattle. (d) Corroboration of the presence of MAP in
the cattle samples using anti-MAP-pAb MRS nanosensors.
FIG. 5 Detection of Mycobacterium avium spp paratuberculosis' genomic marker in clinical samples with hMRS and
direct nPCR. The hMRS detected MAP's IS900 region in
minimally processed blood samples (Cohort 1, n=34). Correlation of the hMRS findings was achieved through pure
DNA extraction from white blood cells and direct nPCR.
Results are means±SE.
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DESCRIPTION OF SUPPLEMENTARY TABLES
Table Sl Spin-spin relaxation times (T2) of crude MAP
DNA samples. Serial dilutions of crude MAP DNA samples
have been utilized to assess the sensitivity of the hMRS
method in minimally processed bacterial cultures. The averages of each independent experiment are listed and the studies' mean.
Table S2 Spin-spin relaxation times (T2) of pure MAP
DNA samples with known genome copies. Three independent experiments were performed on pure DNA samples
obtained from cultured MAP. Correlation between DNA levels and bacterial populations was achieved by quantifying
DNA spectrophotometrically and using the MAP genome
size as a reference.
Table S3 Demographics of cultured clinical isolates that
were screened withhMRS andnPCR. (CD: Crohn's disease,
IBD: inflammatory bowel disease)
Table S4 Clinical data and hMRS results of Cohort 1 blood
samples. Samples from Crohn's disease (CD) patients,
healthy individuals or asymptomatic carriers were analyzed
by direct nPCR and hMRS. Quantification of the MAP
genome copies was achieved in positive ( +) samples using a
training standard curve for crude extracted MAP DNA.
DETAILED DESCRIPTION
Before the present disclosure is described in greater detail,
it is to be understood that this disclosure is not limited to
particular embodiments described, and as such may, of
course, vary. It is also to be understood that the terminology
used herein is for the purpose of describing particular
embodiments only, and is not intended to be limiting, since
the scope of the present disclosure will be limited only by the
appended claims.
Where a range of values is provided, it is understood that
each intervening value, to the tenth of the unit of the lower
limit unless the context clearly dictates otherwise, between
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the upper and lower limit of that range and any other stated or
intervening value in that stated range, is encompassed within
the disclosure. The upper and lower limits of these smaller
ranges may independently be included in the smaller ranges
and are also encompassed within the disclosure, subject to
any specifically excluded limit in the stated range. Where the
stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in
the disclosure.
Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this disclosure
belongs. Although any methods and materials similar or
equivalent to those described herein can also be used in the
practice or testing of the present disclosure, the preferred
methods and materials are now described.
All publications and patents cited in this specification are
herein incorporated by reference as if each individual publication or patent were specifically and individually indicated
to be incorporated by reference and are incorporated herein
by reference to disclose and describe the methods and/or
materials in connection with which the publications are cited.
The citation of any publication is for its disclosure prior to the
filing date and should not be construed as an admission that
the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of
publication provided could be different from the actual publication dates that may need to be independently confirmed.
As will be apparent to those of skill in the art upon reading
this disclosure, each of the individual embodiments described
and illustrated herein has discrete components and features
which may be readily separated from or combined with the
features of any of the other several embodiments without
departing from the scope or spirit of the present disclosure.
Any recited method can be carried out in the order of events
recited or in any other order that is logically possible.
Embodiments of the present disclosure will employ, unless
otherwise indicated, techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, and
the like, which are within the skill of the art. Such techniques
are explained fully in the literature.
It must be noted that, as used in the specification and the
appended claims, the singular forms "a," "an," and "the"
include plural referents unless the context clearly dictates
otherwise. Thus, for example, reference to "a support"
includes a plurality of supports. In this specification and in the
claims that follow, reference will be made to a number of
terms that shall be defined to have the following meanings
unless a contrary intention is apparent.
As used herein, the following terms have the meanings
ascribed to them unless specified otherwise. In this disclosure, "comprises," "comprising," "containing" and "having"
and the like can have the meaning ascribed to them in U.S.
Patent law and can mean "includes," "including," and the like;
"consisting essentially of' or "consists essentially" or the
like, when applied to methods and compositions encompassed by the present disclosure refers to compositions like
those disclosed herein, but which may contain additional
structural groups, composition components or method steps
(or analogs or derivatives thereof as discussed above). Such
additional structural groups, composition components or
method steps, etc., however, do not materially affect the basic
and novel characteristic( s) of the compositions or methods,
compared to those of the corresponding compositions or
methods disclosed herein. "Consisting essentially of' or
"consists essentially" or the like, when applied to methods
and compositions encompassed by the present disclosure

have the meaning ascribed in U.S. Patent law and the term is
open-ended, allowing for the presence of more than that
which is recited so long as basic or novel characteristics of
that which is recited is not changed by the presence of more
than that which is recited, but excludes prior art embodiments.
Bacterial infections are a major global healthcare problem,
and their detection has to be performed in diverse settings and
samples preferably with single-instrument-based diagnostic
modalities, using sensitive and robust probes. Acknowledging these concerns, hybridizing magnetic nanosensors
(hMRS) were used for the detection of the intracellular slowgrowing pathogen Mycobacterium avium spp. paratuberculosis (MAP) that resides in peripheral macrophages, through
the identification of its unique genomic signature. Clinically
relevant samples, including tissue and blood, were screened
with hMRS and gold standard PCR assays. Within less than
an hour, the hMRS identified MAP-positive samples in a
library of laboratory cultures, clinical isolates, blood and
homogenized tissues. Comparison of the hMRS with PCR
methodologies in terms of prediction of disease state revealed
that the hMRS outperformed the other assays, while being
significantly faster (1 hour vs 12 weeks). Additionally, using
a single instrument detection of the intracellular bacterial
target in clinical samples was possible at the genomic and
epitope levels. There are, therefore, clinical and field uses of
the hMRS in the multiplexed identification of microbial
pathogens and other disease-related biomarkers via a single
instrument in clinical and complex environmental samples,
for which the use in detecting MAP and its correlation with a
disease such as diabetes is one example.
MAP is found within the white blood cells of infected
animals with Johne's disease, a form of animal paratuberculosis, which is associated with chronic enteritis, reminiscent
ofCrohn's disease in humans [16]. As early as 1913, Dalziel
noted the clinical similarities of animal paratuberculosis,
intestinal tuberculosis and human chronic granulomatous
enteritis (Crohn's disease) [17]. In humans, Crohn's disease
is a debilitating chronic inflammatory syndrome of the gastrointestinal track and adjacent lymph nodes [17], [18], [19].
The detection of MAP in tissues from patients with Crohn's
disease has been extensively reported. Of particular importance to our study is the report of the presence of MAP in
human peripheral blood [20], [21], [22]. In those studies,
MAP was identified by a culture method followed by PCR
identification of a MAP genomic marker. The whole process
took several months to complete, due to the slow growing
nature of this pathogen. Such a slow detection method not
only delays the diagnosis, but also slows any potential therapeutic intervention [20], [21]. Likewise, difficulties in detecting an intracellular pathogen, such as MAP, hamper studies
aimed at the investigation of the potential role of MAP in
Crohn's disease pathology, as well as the pathogen's impact
on the dairy and beef industries.
Attracted by MAP's slow growing characteristics, intracellular residence and clinical and agricultural relevance,
hMRS was used for the identification of a highly conserved
MAP genomic element (IS900). This unique DNA insertion
sequence has been previously used to identify MAP in clinical samples and cultures by PCR, as it has not been found in
other microorganisms or mycobacteria [23], [24], [25].
Detection is primarily achieved through either direct or culture-based nested PCR (nPCR), which use pure DNA extracts
from infected leukocytes. Both PCR methods sequentially
amplify a 398 bp fragment (amplification round 1) and a 298
bp internal sequence (amplification round 2 ). It was reasoned
that the binding ofhMRS to IS900 would achieve faster and
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more sensitive detection of MAP DNA via magnetic relaxIn a typical example, the hMRS includes a magnetic nanoparticle. The magnetic nanoparticle is typically is comprised
ation in minimally processed clinical samples. Initial studies
of metal and/or metal oxide.
revealed that hMRS can specifically detect MAP's genomic
According to another embodiment, provided is a hybridizmarker without showing cross-reactivity with other mycoing magnetic relaxation nanosensor that includes a magnetic
bacteria. Furthermore, the presence of MAP in homogenized
nanoparticle associated with a nucleic acid that is configured
tissues from Johne's disease cattle was achieved at the
to specifically hybridize to a nucleic acid analyte of interest.
genomic and epitope levels using hMRS and anti-MAP antiIn a typical example, the nucleic acid analyte of interest is of
body-carrying MRS, demonstrating that the MRS technology
a microorganism. In a specific example, the microorganism is
can achieve detection at the genome and organism levels
10 Mycobacterium avium spp. paratuberculosis.
using diverse molecular probes. Finally, a library of 60 blood
Another embodiment disclosed is a method of distinguishsamples from Crohn's disease patients and healthy individuing a mycobacterial related bowel condition from a nonals was screened with hMRS and nPCR assays. Using minimycobacterial related bowel condition in a patient exhibiting
mally processed blood samples, within 60 minutes the hMRS
symptoms of a bowel condition. In a specific example, the
were able to detect the intracellular pathogen and better pre- 15 mycobacterial related bowel condition is inflammatory bowel
dict the clinical condition of an individual (healthy vs Crohn' s
disease (IBD). In an even more specific example, the bowel
disease) than the nPCR methodologies. Specifically, hMRS
condition is Crohn' s disease. A patient exhibiting symptoms
outperformed the 12-week-long culture-based nPCR in cliniof a bowel condition typically will exhibit one or more of the
cal prognosis, as well as the least reliable direct nPCR, which
following symptoms: abdominal pain, vomiting, diarrhea,
are currently used in clinical and research studies. Overall, the 20 rectal bleeding, severe internal cramps/muscle spasms in the
present disclosure demonstrates for the first time the use and
region of the pelvis, weight loss and various associated comvalidation of a novel translational nanotechnology, where the
plaints or diseases like arthritis, pyoderma gangrenosum, porunique water relaxation properties ofiron oxide nanoparticles
ridge-like stool, and primary sclerosing cholangitis.
and the dynamics of the nanoparticle/target interaction were
Typically, a method of distinguishing the conditions
harnessed to achieve a sensitive genomic biomarker detection 25 involves (a) subjecting nucleic acid from a sample obtained
from the patient with at least one hybridizing magnetic relaxsystem for an intracellular pathogen in samples directly
obtained from human patients.
ation nanosensor (hMRS), wherein said hMRS is configured
As used herein, a "sample" or "test sample" can include,
to specifically hybridize to a nucleic acid analyte of interest of
Myca bacterium avium spp. paratuberculosis; and detecting a
but is not limited to, biological material obtained from an
organism or from components of an organism, food sample, 30 change in the magnetic resonance signal from a hMRS
or environmental sample (e.g. water sample or any other
hybridized to a nucleic acid analyte of interest in the nucleic
sample from an environmental source believed to contain a
acid from the sample; wherein a change in the magnetic
microorganism). The test sample may be of any biological
resonance signal indicates that the patient has a mycobactetissue or fluid, for example. In some embodiments, the test
rial related bowel condition. Upon determining that the bowel
sample can be a clinical sample derived from a patient. 35 condition is a mycobacterial related bowel condition, a theraExamples oftest samples include, but are not limited to spupeutically effective amount of an antibiotic composition can
be administered to the patient. Examples of such antibiotics,
tum, cerebrospinal fluid, blood, blood fractions such as serum
include, but are not limited to, metronidazole, ciprofloxacin,
and plasma, blood cells, tissue, biopsy samples, urine, peririfaximin, rifabutin, clarithromycin, and metronidazole/
toneal fluid, pleural fluid, amniotic fluid, vaginal swab, skin,
lymph fluid, synovial fluid, feces, tears, organs, or tumors. A 40 ciprofloxacin combination, vancomycin, azathioprine, inflixtest sample can also include recombinant cells, cell compoimab, tobramycin, or combinations of any of the foregoing.
The term "microorganism" as used herein is intended to
nents, cells grown in vitro, and cell culture constituents
include a virus, bacteria or fungi organism.
including, for example, conditioned medium resulting from
Hybridizing Magnetic Relaxation Nanosensors (hMRS)
the growth of cells in cell culture medium.
According to one embodiment, a method of detecting a 45
In some embodiments, the hMRS includes a capture probe
nucleic acid analyte of interest in a sample is provided. The
associated with a magnetic responsive particle. Typically, the
method includes subjecting nucleic acid from the sample with
capture probe pertains to a nucleic acid. As used herein with
respect to a nucleic acid capture probe, "nucleic acid" refers
at least one hybridizing magnetic relaxation nanosensor
(hMRS), wherein said hMRS is configured to specifically
to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA)
hybridize to the nucleic acid analyte of interest. The method 50 and known analogs, derivatives, or mimetics thereof. A
further includes detecting a change in the magnetic resonance
nucleic acid capture probe can be oligomeric and include
oligonucleotides, oligonucleosides, oligonucleotide analogs,
signal from a hMRS hybridized to a nucleic acid analyte of
interest in the nucleic acid from the sample; thereby detecting
oligonucleotide mimetics and chimeric combinations of
the presence of the nucleic acid analyte of interest in the
these. A nucleic acid capture probe can be single-stranded,
sample. In a specific embodiment, the at least one hMRS 55 double-stranded, circular, branched, or hairpin and can conpertains to a population of hMRS configured to specifically
tain structural elements such as internal or terminal bulges or
loops.
hybridize to the nucleic acid analyte of interest. In another
In some embodiments, a nucleic acid capture probe can
specific embodiment, nucleic acid is isolated from the sample
have a length of at least, or at least about 5, 6, 7, 8, 9, 10, 11,
prior to the subjecting step, to obtain isolated nucleic acid.
Thus, in this specific example, the hMRS is applied to the 60 12, 13,14, 15, 16, 17, 18,19,20,21,22,23,24,25,26,27,28,
29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,
isolated nucleic acid.
46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,
In another specific example, the nucleic acid analyte of
interest is of a microorganism. In a more specific example, the
63,64,65,66,67,68,69,70, 71, 72, 73, 74,75, 76, 77, 78, 79,
microorganism is a mycobacterium. In an even more specific
80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,
embodiment, the microorganism is a strain of Myca bacterium 65 97, 98, 99, or 100 nucleobases, or the nucleic acid capture
probe can have a length within any range bounded by two of
avium spp. paratuberculosis. One specific example of a
the above-mentioned lengths.
nucleic acid analyte is IS900.
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In several embodiments, a nucleic acid capture pro be and a
nucleic acid analyte of interest bind to form a duplex. Such
binding may occur through hybridization. As used herein,
"hybridization" means the pairing of complementary strands
of a nucleic acid capture probe and a nucleic acid analyte of
interest. While not limited to a particular mechanism, the
most common mechanism of pairing involves hydrogen
bonding, which may be Watson-Crick, Hoogsteen or reversed
Hoogsteen hydrogen bonding, between complementary
nucleoside or nucleotide bases (nucleobases) of the strands of
a nucleic acid capture probe and nucleic acid analyte of interest.
In some embodiments, a nucleic acid capture probe and
nucleic acid molecule of interest can hybridize under "stringent conditions," which refer to conditions under which a
nucleic acid capture probe will hybridize to a nucleic acid
molecule of interest, but to a minimal number of other
sequences. A person ofordinary skill in the art will appreciate
that stringent conditions are sequence-dependent and will
vary in different circumstances. High stringency conditions
can be provided, for example, by hybridization in 50% formamide, 5xDenhardt's solution, 5xSSPE, 0.2% SDS at 42°
C., followed by washing in O.lxSSPE, and 0.1 % SDS at 65°
C.
"Complementarity," as used herein, refers to the capacity
for precise pairing between two nucleobases of a nucleic acid
capture probe and nucleic acid analyte of interest. For
example, if a nucleobase at a certain position of a capture
probe is capable of hydrogen bonding with a nucleobase at a
certain position of a nucleic acid analyte of interest, then the
position of hydrogen bonding between the capture probe and
the nucleic acid analyte of interest is considered to be a
complementary position. The capture probe and the analyte
of interest are complementary to each other when a sufficient
number of complementary positions in each molecule are
occupied by nucleobases which can hydrogen bond with each
other. Thus, in some embodiments a nucleic acid capture
probe and nucleic acid analyte of interest are specifically
hybridizable and complementary, which indicate a sufficient
degree of precise pairing or complementarity over a sufficient
number ofnucleobases such that stable and specific binding
occurs.
It will be appreciated that the sequence of a nucleic acid
capture probe need not be 100% complementary to that of a
nucleic acid analyte ofinterest to be specifically hybridizable.
Moreover, a nucleic acid capture probe may hybridize over
one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop
structure, mismatch or hairpin structure). The nucleic acid
capture probes of several embodiments can comprise at least
70%, or at least 75%, or at least 80%, or at least 85%, or at
least 90%, or at least 92%, or at least 95%, or at least 97%, or
at least 98%, or at least 99% sequence complementarity to a
region within the nucleic acid sequence of the analyte of
interest. The degree of complementarity to be specifically
hybridizable can be selected according to well-known principles of hybridization and in accordance with the intended
analytical procedure.
In several embodiments, a nucleic acid capture probe can
comprise one or more oligonucleotide mimetics. The term
"mimetic" includes oligomeric nucleic acids wherein the
furanose ring or the furanose ring and the intemucleotide
linkage are replaced with non-naturally occurring groups.
In certain embodiments, a nucleic acid capture probe comprises a peptide nucleic acid (PNA) oligonucleotide mimetic
(Nielsen et al., Science, 1991, 254, 1497-1500). PNAs have
favorable hybridization properties, high biological stability

and are electrostatically neutral molecules. In PNA oligonucleotide mimetics, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are
bound directly or indirectly to aza nitrogen atoms of the
amide portion of the backbone. Representative U.S. patents
that teach the preparation of PNA oligomeric compounds
include U.S. Pat. Nos. 5,539,082; 5,714,331 and 5,719,262.
PNA compounds can be obtained commercially from
Applied Biosystems (Foster City, Calif., USA). Numerous
modifications to the basic PNA backbone are known in the art
and can be used in several embodiments.
Another class of oligonucleotide mimetic that can be used
for nucleic acid capture probes in several embodiments is
linked morpholino units (morpholino nucleic acid) having
heterocyclic bases attached to the morpholino ring. A number
oflinking groups have been reported that link the morpholino
monomeric units in a morpholino nucleic acid. Morpholinobased oligomeric compounds are non-ionic mimetics of oligonucleotides which are less likely to form undesired interactions with cellular proteins (Dwaine A. Braasch and David
R. Corey, Biochemistry, 2002, 41(14), 4503-4510). Themorpholino class of oligomeric compounds has been prepared
with a variety of different linking groups joining the monomeric subunits.
A further class of oligonucleotide mimetic that can be used
for nucleic acid capture probes in several embodiments is
cyclohexene nucleic acids (CeNA). In CeNA oligonucleotides, the furanose ring normally present in a DNA or RNA
molecule is replaced with a cyclohexenyl ring. CeNA DMT
protected phosphor amidite monomers have been prepared
and used for oligomeric compound synthesis following classical phosphor amidite chemistry. Fully modified CeNA oligomeric compounds and oligonucleotides having specific
positions modified with CeNA have been prepared and studied (Wang et al., J.Am. Chem. Soc, 2000, 122, 8595-8602). In
general the incorporation of CeNA monomers into a DNA
chain increases its stability of a DNA/RNA hybrid. CeNA
oligoadenylates formed complexes with RNA and DNA
complements with similar stability to the native complexes.
In several embodiments, a nucleic acid capture probe can
comprise a locked nucleic acid (LNA), which can increase the
sensitivity and specificity of conventional oligonucleotides,
such as DNA oligonucleotides, for hybridization to short
target sequences such as mature miRNAs, stem-loop precursor miRNAs, pre-miRNAs, siRNAs or other non-coding
RNAs as well as miRNA binding sites in their cognate mRNA
targets, mRNAs, mRNA splice variants, RNA-edited
mRNAs, antisense RNAs and small nucleolar RNAs (snRNA).
Locked nucleic acid (LNA) capture probes are nucleoside
or nucleotide analogues that include at least one LNA monomer (e.g., an LNA nucleoside or LNA nucleotide). LNA
monomers are described in, for example, WO 99/14226, U.S.
Pat. No. 6,043,060, U.S. Pat. No. 6,268,490, WO 01/07455,
WO 01/00641, WO 98/39352, WO 00/56746, WO 00/56748
and WO 00/66604. LNAs have bicyclic sugar moieties "in
which the 2'-hydroxyl group of the ribosyl sugar ring is linked
to the 4' carbon atom of the sugar ring thereby forming a
2'-C,4'-C-oxymethylene linkage to form the bicyclic sugar
moiety (reviewed in Elayadi et al., Curr. Opinion Invens.
Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol, 2001, 8
1-7; and Oram et al., Curr. Opinion Mo!. Ther., 2001, 3,
239-243; see also U.S. Pat. Nos. 6,268,490 and 6,670,461).
The synthesis and preparation of the LNA monomers
adenine, cytosine, guanine, 5-methylcytosine, thymine and
uracil, along with their oligomerization, and nucleic acid
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recognition properties have been described (Koshkin et al.,
Tetrahedron, 1998, 54, 3607-3630).
Analogs of LNA, phosphorothioate-LNA and 2'-thioLNAs, have also been prepared (Kumar et al., Bioorg. Med.
Chem. Lett., 1998, 8, 2219-2222). Preparation of locked
nucleoside analogs containing oligodeoxyribonucleotide
duplexes as substrates for nucleic acid polymerases has also
been described (Wengel et al., WO 99/14226). Furthermore,
synthesis of 2'-amino-LNA, a novel conformationally
restricted high-affinity oligonucleotide analog has been
described in the art (Singh et al., J. Org. Chem., 1998, 63,
10035-10039). In addition, 2'-Amino- and 2'-methylaminoLNA's have been prepared and the thermal stability of their
duplexes with complementary RNA and DNA strands has
been previously reported.
In several embodiments, a nucleic acid capture probe can
include a non-native, degenerate, or universal base such as
inosine, xathanine, hypoxathanine, isocytosine, isoguanine,
5-methylcytosine, 5-hydroxymethyl cytosine, 2-aminoadenine, 6-methyl adenine, 6-methyl guanine, 2-propyl guanine, 2-propyl adenine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 15-halouracil, 15-halocytosine, 5-propynyl uracil,
5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo
thymine, 5-uracil, 4-thiouracil, 8-halo adenine or guanine,
8-amino adenine or guanine, 8-thiol adenine or guanine,
8-thioalkyl adenine or guanine, 8-hydroxyl adenine or guanine, 5-halo substituted uracil or cytosine, 7-methylguanine,
7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, or
the like. In some embodiments, a nucleic acid capture probe
can include isocytosine and/or isoguanine in order to reduce
non-specific hybridization as generally described in U.S. Pat.
No. 5,681,702.
In several embodiments, a nucleic acid capture probe can
comprise an "aptamer" to bind to a nucleic acid or polypeptide analyte of interest. Aptamers are described in U.S. Pat.
Nos. 5,270,163; 5,475,096; 5,567,588; 5,595,877; 5,637,459;
5,683,867; and 5,705,337; which are herein incorporated by
reference in their entireties. Aptamers can bind to various
molecular targets such as small molecules, proteins, and
nucleic acids.
In several embodiments, the particle associated with the
nucleic acid capture probe comprises a nanoparticle, nanosphere, microcapsule, nanocapsule, microsphere, microparticle, bead, colloid, aggregate, flocculate, insoluble salt,
emulsion, crystal, detergent, surfactant, dendrimer, copolymer, block polymer, nucleic acid, carbohydrate, lipid, liposome, or insoluble complex. It is contemplated that these
types of particles can have any size in the picometer, nanometer, micrometer, or millimeter range along any dimensional
axis. As used herein, the term "nanoparticle" refers to any
particle having a greatest dimension (e.g., diameter) that is
less than about 2500 nm. In some embodiments, the nanoparticle is a solid or a semi-solid. In some embodiments, the
nanoparticle is generally centrosymmetric. In some embodiments, the nanoparticle contains a generally uniform dispersion of solid components.
Nanoparticles can have a characteristic dimension of less
than about 1 micrometer, where the characteristic dimension
of a particle is the diameter of a perfect sphere having the
same volume as the particle. For example, the nanoparticle
may have a characteristic dimension that is less than 500 nm,
400 nm, 300 nm, 250 nm, 200 nm, 180 nm, 150 nm, 120 nm,
100 nm, 90 nm, 80 nm, 70 nm, 60 nm, 50 nm, 40 nm, 30 nm,
or 20 nm, or any number in between the aforementioned sizes.
In some embodiments, the nanoparticle can have a characteristic dimension of 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm,

70nm, 80nm, 90nm, lOOnm, 120nm, 150nm, 180nm, 200
nm, 250 nm or 300 nm, or any number in between the aforementioned sizes. In other embodiments, the nanoparticle can
have a characteristic dimension of 10-500 nm, 10-400 nm,
10-300 nm, 10-250 nm, 10-200 nm, 10-150 nm, 10-100 nm,
10-75 nm, 10-50 nm, 50-500 nm, 50-400 nm, 50-300 nm,
50-200 nm, 50-150 nm, 50-100 nm, 50-75 nm, 100-500 nm,
100-400nm, 100-300nm, 100-250nm, 100-200nm, 100-150
nm, 150-500 nm, 150-400 nm, 150-300 nm, 150-250 nm,
150-200 nm, 200-500 nm, 200-400 nm, 200-300 nm, 200-250
nm, 200-500 nm, 200-400 nm or 200-300 nm.
In several embodiments, a particle comprises a metal particle, such as an Au, Ag, Pd, Pt, Cu, Ni, Co, Fe (e.g. iron
sulfide), Mn, Ru, Rh, Os, or Ir particle. In various embodiments, a particle comprises a metal oxide particle. Examples
of suitable metal oxide particles include zinc oxide, titanium
(di)oxide, iron oxide, silver oxide, copper oxide, aluminum
oxide, or silicon (di)oxide particles. In certain embodiments,
a particle comprises a magnetic particle, such as a magnetic
bead, nanoparticle, microparticle, and the like.
Where the analyte of interest is a nucleic acid molecule,
several embodiments relate to methods of detecting a nucleic
acid molecule of interest in a sample comprising: providing a
hMRS comprising a nucleic acid capture probe associated
with a magnetic responsive nanoparticle, wherein the capture
probe is capable ofhybridizing to the nucleic acid molecule of
interest to form a duplex; applying a sample for which the
presence or absence of the nucleic acid molecule of interest is
to be determined to the hMRS under conditions in which the
nucleic acid molecule of interest, when present, and the capture probe sequence-specifically hybridize to form a
duplex; and determining the presence or absence of the
nucleic acid molecule of interest by detecting an alteration in
a magnetic property of the hMRS or sample. In a specific
example, the alteration in a magnetic property is a change in
the magnetic resonance signal of the hMRS or the environment surrounding the hMRS. A change in the magnetic resonance signal can include an increase or decrease in the T2 of
the hMRS and/or sample. This can be further defined in
relation to a negative control. In some aspects, the concentration of the nucleic acid analyte of interest in the sample is
measured. Detecting and/or measuring the concentration of a
nucleic acid molecule of interest in a sample can be done in
real-time and/or in multiplex with other analytes ofinterest or
samples.
Typically, the target analyte is isolated before being subjected to hMRS. The terms "isolate", "isolated" or"isolation"
when used with respect to the target analyte, e.g., nucleic acid
analyte, means enriching the target analyte relative to its
natural environment. Thus, enrichment could include partial
purification or full purification, but in most cases simply
means removing components from the crude sample. In the
case of a blood sample, isolation might include a centrifugation step and removing a portion of the centrifuged sample.
There are varieties of ways that the nanoparticles can be
prepared, but typically, the result involves a nanoparticle with
functional groups that can be used to associate the nanoparticle to the binding moiety. The terms "association", "associating" or "associate" with respect to the interaction between
the nucleic acid capture probe and the particle generally refers
to the adherence interaction (typically covalent binding) that
is direct, such as directly to the material of which the particle
is composed, or indirect, such as interaction with a coating
(e.g. polymer coating) on the particle. Typically, association
of the nucleic acid can be associated through non-polymer
surface functionalization of the particle or via functionalized
polymers on the particle. According to one embodiment, the
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hMRS is a nanoparticle that is composed of a magnetic metal
oxide and includes one or more functional groups, e.g., a
polymer comprising one or more functional groups. When
polymers are included, they contain functional groups that
enable the nucleic acid to be attached to the nanoparticle to
form the conjugate. The polymer can be a natural polymer, a
synthetic polymer, a combination of natural and synthetic
polymers, or derivatives of each type. The functional groups
can be carboxy, amino, or sulfhydryl groups. In some
embodiments, the binding moiety is attached to the nanoparticle through disulfide groups. The metal oxides can also be
associated with non-polymer functional groups to form the
nanoparticles.
In one example, nucleic acids can be linked to the metal
oxide through covalent attachment to a functionalized polymerorto non-polymeric surface-functionalizedmetal oxides.
In the latter method, the nanoparticles can be synthesized
according to the method of Albrecht et al., Biochimie, 80
(5-6): 379-90, 1998. Dimercapto-succinic acid is coupled to
the iron oxide and provides a carboxyl functional group. By
functionalized is meant the presence of amino or carboxyl or
other reactive groups.
In another example, oligonucleotides are attached to magnetic nanoparticles via a functionalized polymer associated
with the metal oxide. In some embodiments, the polymer is
hydrophilic. In a specific embodiment, the conjugates are
made using oligonucleotides that have terminal amino, sulfhydryl, or phosphate groups, and superparamagnetic iron
oxide nanoparticles bearing amino or carboxy groups on a
hydrophilic polymer. There are several methods for synthesizing carboxy and amino derivatized-nanoparticles. Methods for synthesizing functionalized, coated nanoparticles are
discussed in further detail below.
Carboxy functionalized nanoparticles can be made, for
example, according to the method of Gorman (see WO
00/61191). In this method, reduced carboxymethyl (CM)
dextran is synthesized from commercial dextran. The CMdextran and iron salts are mixed together and are then neutralized with ammonium hydroxide. The resulting carboxy
functionalized nanoparticles can be used for coupling amino
functionalized nucleic acids.
Carboxy-functionalized nanoparticles can also be made
from polysaccharide coated nanoparticles by reaction with
bromo or chloroacetic acid in strong base to attach carboxyl
groups. In addition, carboxy-functionalized particles can be
made from amino-functionalized nanoparticles by converting
amino to carboxy groups by the use of reagents such as
succinic anhydride or maleic anhydride.
Nanoparticles can also be synthesized according to the
methodofMolday (Molday, R. S, andD. MacKenzie, "Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells," J. Immunol. Methods,
1982, 52(3):353-67, and treated with periodate to form aldehyde groups. The aldehyde-containing nanoparticles can then
be reacted with a diamine (e.g., ethylene diamine or hexanediamine ), which will form a Schiff base, followed by
reduction with sodium borohydride or sodium cyanoborohydride.
Dextran-coated nanoparticles can be made and crosslinked with epichlorohydrin. The addition of ammonia will
react with epoxy groups to generate amine groups, see Hagemann, D., et al., Improvement ofMRI probes to allow efficient
detection ofgene expression Bioconjug. Chem. 2000. 11(6):
941-6, and Josephson et al., "High-efficiency intracellular
magnetic labeling with novel superparamagnetic-Tat peptide
conjugates," Bioconjug. Chem., 1999, 10(2):186-91. This

material is known as cross-linked iron oxide or "CLIO" and
when functionalized with amine is referred to as amine-CLIO
or NH 2 -CLIO.
Carboxy-functionalized nanoparticles can be converted to
amino-functionalized magnetic particles by the use of watersoluble carbodiimides and diamines such as ethylene diamine
or hexane diamine.
Avidin or streptavidin can be attached to nanoparticles for
use with a biotinylated binding moiety, such as an nucleic
acid. See e.g., Shen et al., "Magnetically labeled secretin
retains receptor affinity to pancreas acinar cells," Bioconjug.
Chem., 1996, 7(3):311-6. Similarly, biotin can be attached to
a nanoparticle for use with an avidin-labeled binding moiety.
Another example of a polymer coating for the particle is a
polyacrylic acid. The method of producing these is described
further in the Examples section.
According to an alternative embodiment, provided is a
method to detect for the presence of antibodies in a biological
sample. The method may include contacting the sample with
a nanosensor that includes a nanoparticle associated with a
binding molecule (such as a polypeptide) having an epitope to
an antibody of interest. The term "polypeptide" as used herein
pertains to two or more linked amino acids, and would include
proteins. For example, if an antibody of interest is present in
the sample, it would bind to the epitope containing polypeptide which would modulate the resonance signal of the sample
and/or nano sensor. The polypeptide could pertain to a protein
specific to a certain microorganism (such as MAP protein). If
a subject has been exposed to a certain microorganism, the
subject will most likely generate antibodies against that
organism. Thus, if a change magnetic resonance signal is
detected, then this indicates that the subject has been exposed.
This type of assay is analogous to the classic TB skin test.
However, instead of detect an immune reaction on the skin
due to the presence of antibodies, the antibody-specific
nano sensors will detect the presence of antibodies in a sample
through observed changes in a magnetic response.
According to a related embodiment, provided is an antibody-specific nanosensor. The antibody-specific nanosensor
includes a magnetically responsive nanoparticle associated
with a molecule having an epitope to an antibody of interest.
In a specific embodiment, the molecule having an epitope to
an antibody of interest is a polypeptide.
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The detection ofMAP's 15900 genomic marker relies on
DNA isolation and subsequent amplification and detection
via PCR. Typically, DNA from peripheral leukocytes found in
the buffy coat (Direct nPCR) or leukocyte-derived cultured
bacteria (Culture-based nPCR) is first isolated in a multistep
protocol [21], yielding bacterial DNA of high quality (FIG.
la). However, this approach often times compromises DNA
yield, which may impede MAP identification. In subsequent
steps, the bacterial DNA is subjected to two 3-hour-long
polymerase-mediated amplification rounds of the IS900
locus, followed by gel electrophoresis. To facilitate faster
detection via magnetic relaxation, a single hMRS probe was
designed that hybridizes with the unique IS900 sequence
within the MAP plasmid. These hMRS are composed of a
polyacrylic acid-coated iron oxide nanoparticle onto which
an oligonucleotide sequence (ATGTGGTTGCTGTGT (SEQ
ID NO. 1)) complementary to the IS900 sequence in MAP is
conjugated to facilitate binding and detection. The resulting
MAP specific hMRS had a diameter of78±3 nm, zeta paten-
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tial value of -35 mV, an average of 55 oligonucleotides per
nanoparticle, with Rl and R2 relaxivities (at 0.47T) of 45
mM-1 s-1 and 60 mM-1 s-1 respectively. We anticipated that
hMRS could utilize crude DNA, obtained from isolated buffy
coats that have been subjected to heating (FIG. la). It is well
reported that heating of peripheral leukocytes accomplishes
first the release of a pathogen from intracellular compartments [21], such as phagosomes, due to extensive pore formation on the host cell's plasma membrane and organelles'
phospholipid-containing membrane. Once exposed to high
temperatures, the pathogen's structural integrity is affected,
leading to release of its genomic DNA to the aqueous milieu.
A series of heating and cooling procedures on the isolated
MAP DNA plasmid in the presence of hMRS reduces the
DNA torsional strain, facilitating annealing andhydridization
of the hMRS onto the IS900 region of the MAP genome (FIG.
lb). Decreasing the sample's temperature can return the DNA
to a higher structural order, with the hMRS still binding to the
MAP genome and inducing increases in the sample's magnetic resonance signal. Specifically, the hMRS were able to
bind to MAP DNA after two short heating rounds (3 min each
at 95° C.), followed by unassisted cooling to room temperature. The fast changes in the magnetic resonance signal were
monitored with a compact nuclear magnetic resonance instrument (0.47T, Bruker, Minispec), recording increases in the
sample's transverse relaxation times (li.T2+, where
T2(sample)>T2( control)). Within 30 minutes after removing
the samples from heat, significant and reproducible changes
were observed prompting us to set this time-point as the
hMRS readout point (FIG. 7). Based on the observation that
the sample's T2 times were higher than those of the sterile
control throughout the experimental time course, it was
deduced that the hMRS first bound to the relaxed circular
MAP DNA that was heated, while the hMRS still remained
bound to the cooled DNA as it was returning to its supercoil
form. These results were corroborated by dynamic light scattering studies that showed no clustering of the nanoparticle
suspension upon addition of the isolated MAP genome, since
the nanoparticle diameter was found to be 81±5 nm. Likely,
this may be attributed to the fact that during sample cooling
the DNA returned to its supercoiled conformation, which can
be in the order of a few nanometers, and as a result nominally
altering the overall size of the hybridizing nanoparticle-DNA
complex.
hMRS are Specific and Sensitive Probes
Specificity is a critical component of any assay, supporting
correct diagnosis and therapeutic intervention. To determine
the specificity of the hMRS, we incubated the hMRS (6 µg
Fe/mL) with pure DNA extracts from various mycobacteria
and monitored changes in T2 signal.
Within 30 minutes, results indicated that only samples
containing MAP DNA exhibited a high li. T2+ signal, being
attributed to the hMRS-MAP DNA binding (FIG. 2a). Additionally, the hMRS were still able to identify their target in a
solution with a mixture of MAP and other mycobacterial
DNA (FIG. 2a). This indicates that the hMRS are sensitive
and specific, without being affected by the presence of other
mycobacterial DNA. Furthermore, addition of a synthetic
oligonucleotide complementary to the IS900 sequence abrogated the signal of the hMRS upon MAP DNA addition,
confirming the specificity of the hMRS probe (data not
shown). Since other microorganisms' DNA might be found in
a clinical sample, we examined ifthe hMRS could differentiate between MAP and common Gram positive and Gram
negative bacteria, as well as different types of mycobacteria.
Results showed that only the MAP sample yielded a high
li. T2+, whereas the other bacterial DNA samples exhibited

signal proximal to that of the sterile control (FIG. 2a). These
data hint the potential use of the hMRS and magnetic relaxation detection for the fast and specific detection of MAP
DNA.
In subsequent studies, whether the hMRS could quantify
MAP DNA was determined. MAP DNA was isolated using
either an elaborate multistep extraction protocol to obtain
pure DNA, or a fast 30-minute boiling-based methodology to
obtain crude DNA. After a 30-minute incubation period, the
hMRS were able to detect MAP DNA in both pure and crude
DNA preparations, exhibiting concentration-dependent
li.T2+ changes (FIGS. 2b and 2c, Table Sl). The observed
MAP concentration response pattern exhibited a high magnetic resonance signal (ti. T2+) at low target concentration
levels and low signals at higher DNA concentrations. This
suggests that the binding between the hMRS and MAP DNA
was facilitated via low valency interaction, as previously
described in other models [11]. This unique interaction
mechanism provides enhanced sensitivity during the screening of scarce biomarkers, since high signal is desired at low
target concentrations. Quantification of the number of oligonucleotides on the hMRS probe revealed that on average there
were 55 oligonucleotides (oligos) per hMRS. This level of
oligos per nanoparticle is in line with previous reports, where
valency grafting of 46 oligos per nanoparticle exhibited a low
valency binding behavior, whereas a nanoparticle with 368
oligos obeyed a high valency mechanism [12]. A low-valency-based detection approach is ideal for the identification
of MAP in clinical samples, since it will induce a prominent
li. T2+ signal at low numbers of MAP. Based on the findings
that both pure and crude MAP DNA exhibited similar hMRS
quantification patterns, it was deduced that the hMRS assay
can detect IS900 independent of the sample's DNA extraction
methodology. Although higher changes were recorded in
pure MAP DNA samples, both extraction methodologies had
equivalent detection thresholds, reaching low femtogram
(10-15) levels. Potentially the differences in the magnitude of
the li. T2+ from pure and crude MAP DNA might be attributed
to the sample's unique characteristics. It is plausible that the
high purity of the pure DNA extracts is associated with marginal protein and lipid levels, resulting in lower viscosity.
Alternatively, a crude MAP DNA sample may have substantially higher content of proteins and lipids, thus higher viscosity, which may be reflected in lower li. T2+ values upon
IS9000-hMRS hybridization. We then examined whether
nested PCR (nPCR) can achieve comparable sensitivity using
crude MAP DNA. We decided to compare our hMRS method
with nPCR as opposed to reverse transcriptase PCR (RTPCR), due to the fact that MAP is an intracellular pathogen
that grows very slowly. Similar to other intracellular microorganisms, it can be dormant and reduce its metabolism,
suppressing transcriptional and translational activity [21]. As
a result, the transcripts (mRNA) of even housekeeping genes
are nominal and cannot be used in RT-PCR diagnostics.
Therefore, nPCR is the technique most typically used for
MAP detection [21]. Using nPCR, after two 3-hour-long
cycles and electrophoresis, nPCR was not able to detect MAP
IS900 in samples containing crude MAP DNA (FIG. 8). This
demonstrates the sensitivity and robustness ofhMRS to rapidly detect their target even under conditions of interference,
which prevent the use of traditional enzyme-based methods.
In line with this, recent studies have demonstrated that
nucleic-acid-decorated nanostructures can be highly stable
even in serum-containing media and avoid non-specific protein and nuclease interactions, due to the steric inaccessibility
and high local salt concentration introduced by the nanoparticles' DNA strands [26]. Subsequently, we then compared
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hMRS and nPCR using purified DNA extracts instead. Also
considering the size of MAP's genome (4,829,781 bp) and
the average molecular weight of a base pair (MW: 650), we
calculated the mass of a single MAP genome copy to be equal
to 5.2 fg. This value is comparable to that determined experimentally in previous reports [27]. Hence, we accordingly
prepared serial dilutions of MAP DNA with known genome
copy numbers. hMRS and magnetic relaxation detection
were able to detect a single copy of MAP DNA within 30
minutes, whereas nPCR was able to achieve similar, although
not as sensitive, detection (5 bacteria) only after the second
amplification round (FIGS. 2d and Ze, Table s2 ). This trans!ates to a total readout time for nPCR of more than 6 hours,
with the need of more reagents, such as primers and enzymes,
as well as labor and equipment time. Intriguingly though, the
hMRS had a single genome-copy detection threshold when
crude MAP DNA was used, without compromising their sensitivity in this minimally processed sample (FIG. 9). Overall,
these data demonstrate that hMRS can achieve fast single
MAP genome detection even in crude DNA samples, outperforming nPCR in readout time, sensitivity and robustness.
hMRS Achieve Genome-Based Detection of the Intracellular
Pathogen Mycobacterium avium Spp. Paratuberculosis in
Cultured Clinical Isolates and Tissue Samples
Since the hMRS detected MAP DNA in samples from pure
bacterial cultures, we investigated if the nanosensors could
identify their targets in more complex samples, such as cultured clinical isolates and homogenized tissue preparations.
We first screened cultures of clinical isolates from Crohn's
disease patients with the hMRS and compared these results
with nPCR. Specifically, we used crude DNA for the hMRS
and pure DNA for the nPCR, since nPCR cannot utilize crude
DNA. Following a single-step procedure, crude DNA
obtained from cultured isolates of healthy individuals yielded
a magnetic signal change that was comparable to that of the
sterile culture medium (ti. T2+= 1.3±0.2 ms), establishing this
magnetic signal change as the hMRS negative control baseline. Further studies indicated that the hMRS were able to
rapidly detect MAP in several clinical isolates with good
correlation to the culture-based nPCR, indicating that the
hMRS can quickly detect the IS900 biomarker in minimally
processed cultured clinical isolates (FIG. 3, Table S3). Out of
the ten cultures screened, one sample from a culture of an ilea!
biopsy (GN2') was identified as positive by the hMRS, yet
negative by nPCR. A false negative result with culturing
methods can occur when either low amounts of the pathogen
are present in the collected sample or when the pathogen is
not viable to properly grow in culture. This prompted us to
analyze the culture sample from the corresponding patient's
blood (GN2). We reasoned that viable MAP could be present
in the patient's leucocytes, granting correct diagnosis.
Indeed, culture from the blood sample GN2 was identified as
positive in agreement with the hMRS diagnosis and clinical
sympthology. Therefore, nPCR may have failed to detect
IS900 in ilea! biopsy GN2' perhaps due to either low levels of
the pathogen or the presence of interferences in the biopsy
sample that inhibited growth of the pathogen in culture. Overall, these results suggest that the high sensitivity of hMRS
facilitates the positive identification of MAP in blood and
biopsy samples, whereas PCR techniques were not always
successful in identifying MAP.
Next, we screened various ilea! biopsies from Crohn's
disease patients for the presence of MAP at the genomic and
epitope levels using magnetic relaxation. We performed these
studies since clinical diagnostics frequently require the identification of a biomarker at multiple levels. For instance, the
aberrant activity of an oncogene has to be evaluated at the
transcriptional, translational and post-translational levels, in
order to understand causality, delineate disease dynamics and

identify optimal therapy [28], [29], [30]. For these studies, in
addition to the MAP IS900 hybridizing sensor (hMRS), we
prepared a MAP-epitope-sensing MRS (diameter=92±4 nm,
zeta potential=-31 mV, an average of 2 antibodies per nanoparticle, Rl =48 mM-ls-1 and R2=57 mM-ls-1) that identifies a conserved MAP bacterial surface antigen [31].
Despite their different detecting mechanisms (oligonucleotide probe vs antibody), binding site topology and target
characteristics (DNA vs surface epitope ), both MRS provided
a li. T2+ signal for all samples with clinical symptomology
(Pl-P4, FIGS. 4a and 4b ), whereas the sample from a healthy
individual (Hl, FIGS. 4a and 4b), exhibited nominal magnetic signal changes. Independent confirmation of the MAP
MRS findings was achieved by performing DNA extraction
and nPCR analysis. In addition, we used both the hMRS and
epitope MRS to screen for the presence of MAP in tissue
samples from cattle infected with Johne's disease. Since
MAP causes Johne's disease in cattle, we investigated if these
probes can identify this intracellular pathogen at the genomic
and epitope levels in homogenized tissue samples. Results
showed significant magnetic signal changes in all tissues
from infected animals (FIGS. 4c and 4d), demonstrating that
hMRS and epitope MRS can quickly detect MAP in clinically
relevant samples at both the genomic and epitope levels. It is
interesting to note that in both human biopsies from Crohn's
patients and tissues from animals with Johne' s disease, the
magnetic relaxation signal obtained with the hMRS probe
correlates with that obtained with the epitope-sensing MRS
for the same sample. The differences in the li. T2+ among the
animal tissue samples might be attributed to the fact that the
spatial concentration of MAP differs among the various tissues within the same animal due to Johne's disease pathophysiology. Overall, these results indicate that these probes
can be used for the screening of complex tissue samples with
minimal or no sample preparation, supporting clinical decision making.
hMRS Quickly Detect MAP DNA in Peripheral Blood
Acknowledging previous reports that identified MAP in
the blood of Crohn's disease patients, we sought to screen
blood samples from healthy individuals and Crohn's disease
patients for the presence ofIS900 (n=34). For this, we chose
to screen MAP' s IS900 genomic marker, rather than a protein
(epitope) marker, since the later involves the use of anti-MAP
antibodies that are difficult to reproducibly generate while
avoiding antibody batch variabilities. In addition, a DNAbased hybridizing MRS would be more robust and selective
than an antibody-based MRS. Peripheral blood was collected
and DNA was directly isolated from white blood cells, via
either a 30-minutes crude DNA extraction protocol for hMRS
or a multistep high purity and quality DNA isolation procedure for direct nPCR screening. Direct nPCR for the MAP
IS900 biomarker provided conclusive results about the pathogen' s presence in these samples, hence these samples established the first peripheral blood cohort (Cohort 1). In this
cohort, positive samples were defined as those samples where
a prominent band corresponding to IS900 was observed and
negative samples were those where no visible band was
observed at all. Control and Cohort 1 samples were screened
with hMRS, after a 30-minutes crude DNA extraction protocol from white blood cells. Crude DNA extracted from control samples induced small changes in the magnetic signal
(li.T2+=1.3±0.1 ms), which served as the hMRS reference
point. Interestingly, results obtained with hMRS and magnetic relaxation detection using crude DNA samples from
patients within Cohort 1 were in complete agreement with
results obtained with direct nPCR that used pure DNA
samples (FIG. 5, Table S4). Addition of a synthetic target
complementary to hMRS led to signal abrogation in the
samples that had been identified as MAP positive, confirming
the specificity of the assay. This indicates that the hMRS can
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detect their target in minimally processed blood samples,
TABLE I-continued
while eliminating lengthy sample preparation procedures.
Clinical data and hMRS results of minimally
Next, a second cohort of blood samples (Cohort 2, Table 1)
processed blood samples (Cohort 2)
was represented by samples where direct nPCR analysis provided dubious results. In samples within this cohort, classifihMRS
cation as either positive or negative was not possible due to
CultureAge
MAP
the presence of smeared or faint bands. The presence of these
(bacDiagSam- (years)/
Direct
based
L\.T2
dubious samples, either false-positives or false-negatives, is a
no sis
PCR
PCR
MAP
(ms)
teria)
ple
sex
major problem with current nPCR techniques. Therefore, we
+ (3/3)
M/56
CD
7.6
12826
+
examined if the hMRS performs better than direct nPCR and 1o BS
B6
F/57
Healthy
4.2
465264
+ (3/3)
+
culture-basednPCR in determining if an individual is positive
B7
M/28
CD
7.5
13963
+ (3/3)
+
or negative based on his/her clinical state (in this case being
+ (3/3)
BS
F/31
Healthy
7.0
24006
+
Crohn's positive or healthy). For the culture-based nPCR,
B9
M/18
CD
760
+ (3/3) 10.3
+
BIO M/28
CD
5.2
162513
+ (3/3)
inoculants from white blood cells were incubated for 12
+
CD
4.4
400959
+ (3/3)
+
weeks in specialized mycobacterial media (n=26), allowing 15 Bll F/16
- (0/3)
B12 F/24
Healthy
0.2
0
+
the potential growth of any viable MAP bacteria. After this
- (0/3)
B13
F/61
Healthy
0.4
0
+
long incubation period, pure DNA extraction was performed,
- (0/3)
B14 M/65
Healthy
0.1
0
+
followed by nPCR analysis. Interestingly, the culture-based
- (0/3)
B15
F/62
Healthy
0.1
0
+
nPCR was better in predicting disease than direct nPCR,
- (0/3)
B16 F/23
CD
0.7
0
+
- (0/3)
Healthy
0.6
0
+
which was performed on pure DNA extracted from white 20 B17 F/48
- (0/3)
B18 M/19
CD
0.0
0
+
blood cells readily after venipuncture (blood draw) (FIGS. 6a
- (0/3)
B19 F/26
Healthy
0.4
0
+
and 6b). This may be attributed to the ability of bacterial
- (0/3)
CD
0.0
0
B20 M/43
+
culturing to provide more high-quality MAP DNA, as
- (0/3)
B21
F/50
CD
0.1
0
+
opposed to DNA directly obtained from white blood cells.
- (0/3)
B22 F/12
Healthy
0.5
0
+
+
- (0/3)
B23
M/57
Healthy
0.0
0
+
+
Additionally, it is plausible that culturing can facilitate
- (0/3)
Healthy
0.6
0
+
+
growth of even low populations of bacteria in optimal condi- 25 B24 F/23
- (0/3)
B25
M/61
Healthy
0.2
0
+
+
tions, whereas direct pure DNA isolation from white blood
- (0/3)
B26 F/49
Healthy
0.3
0
+
+
cells may result in low genome recoveries of rare bacteria
throughout its multiple steps and presence of interferences,
like nucleases, cytosolic proteins and membrane lipids. ComDiscussion
paring both PCR setups with the crude DNA hMRS method- 30
One of the aims of the studies in this Example was to
ology, we found that the nanoparticle-based method outperdevelop and test a nanoparticle-based assay for the sensitive
formed both PCR-based methods in correlating MAP's
detection of genomic bacterial biomarkers of an intracellular
presence and disease state (FIGS. 6a and 6b). This hints the
pathogen in clinical samples. Preliminary studies demonhMRS' sensitivity, and the ability of the crude DNA extraction method to provide adequate DNA levels that are suffi- 35 strated that the hMRS can specifically detect a conserved
genomic element (IS900) in MAP' s genome, and not in other
cient to facilitate improved bacterial detection. Furthermore,
microorganisms. Through additional studies, it has been
a receiver operating characteristic (ROC) analysis based on
identified that the sensitivity of the nanosensors was equal to
hMRS-mediated MAP quantification indicated that hMRS
one genome copy even in minimally processed samples,
can provide improved clinical diagnosis than the qualitative
(positive vs negative) nested PCR assays (FIG. 6a, Table 1).
allowing detection of MAP in clinical isolates, tissue homo40
Specifically, hMRS were able to better correlate bacterial
genates and blood. Compared to nPCR, hMRS had improved
biomarker presence and Crohn' s disease symptomology than
performance and yielded faster results. Consequently, this
both direct and culture-basednPCR. This suggests the potentranslates to lower costs, since the magnetic nanosensors are
tial use of hMRS for the future investigation of complex
fairly easy and cheap to manufacture in larger quantities, and
disease and the role of various disease effectors and contributors, to better understand pathogenesis' mechanisms and its 45 the assay does not require multiple oligonucleotide primer
pairs, expensive enzymes and nucleotides. Detection was
dynamic interactions. Taken together, this data prove that
performed using a simple table-top relaxometer that meahMRS can rapidly detect a unique nucleic acid signature of an
sured the increase in the water proton relaxation time (NMR
intracellular pathogen in clinical samples with improved
signal) that occurred after the hMRS probes bound to their
fidelity and higher sensitivity than PCR. This enhanced detection translates into a more sensitive pathogen detection and so genomic target. The unprecedented detection limit of this
more accurate diagnosis of the disease, providing important
technique is due to the build-in water relaxation amplification
clinical information for successful treatment and therapeutic
that results upon a single binding event. The T2 relaxation
interventions due to early diagnosis.
times ofhundreds of thousands of water molecules surrounding the hMRS probes increase upon binding of a single probe
TABLE 1
55 to the target. This is also facilitated by the low valency of the
hMRS probe that induces drastic changes at low concentraClinical data and hMRS results of minimally
of the target, or in this case low copy numbers of the
tion
processed blood samples (Cohort 2)
genomic target. This approach contrasts with previous maghMRS
netic relaxation approaches that rely on the use of two mag60 netic nanoparticle probes that hybridize to adjacent
CultureAge
MAP
sequences on a DNA target, facilitating clustering of the
Sam- (years)/
(bacDiagbased
Direct
L\.T2
nanoparticles with a corresponding decrease in the T2 relaxteria)
ple
sex
nos is
PCR
PCR
MAP
(ms)
ation times [32], [33]. Since our approach does not rely on
5348
+ (3/3)
Bl
F/51
CD
8.4
+
nanoparticle clustering and only the binding of the nanoparB2
F/27
CD
8.6
4609
+ (3/3)
+
65 ticle is sufficient for detection, a faster, more sensitive mag+ (3/3)
B3
F/73
Healthy
9.1
2542
+
+ (3/3)
B4
F/50
CD
3.4
1088531
netic relaxation assay that rivals PCR has been developed for
+
the screening of an intracellular pathogen genomic marker.
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Apart from a table-top relaxometer, portable magnetic relaxometers have been developed, suitable for point-of-care
screening with hMRS [34].
hMRS can be used for the detection of diverse targets in
complex media, including turbid and opaque clinical samples
[11], [12]. Herein, our results demonstrate that the hMRS
binding can achieve the unprecedented and fast detection of a
single genome copy of an intracellular pathogen. This is
critical for the identification of extremely virulent pathogens.
As MAP is an intracellular pathogen similar to M. tuberculosis, its detection is difficult, due to the pathogen's residence
within an infected leukocyte's organelles. Thus contemporary diagnostic methodologies rely on cell isolation, cell lysis
and nucleic acid isolation, in order to yield high purity DNA.
This renders MAP's detection problematic since the microorganism has to be isolated from highly complex samples,
such as blood or severely inflamed tissue biopsies, before
amplification and detection via PCR analysis. Apart from
DNA quality, the quantity of MAP DNA can affect the outcome of PCR. For instance, low MAP DNA levels from a
clinical sample may not be successfully amplified through
direct nPCR or biological matrix components can affect the
polymerase activity, yielding false-negative or dubious
results. In our studies, a significant number of samples that
were identified as MAP dubious by direct nPCR were found
to be positive by culture-based nPCR and hMRS (Cohort 2),
indicating that the pathogen was originally present in the
patient' s blood (albeit in low amounts) and successfully grew
in culture at adequate levels.
The culture-basednPCR, relies on the availability of viable
bacteria in the clinical sample that can be grown in culture in
sufficient amounts before nPCR. Most clinical microbial
diagnostics rely on the growth of the pathogen in culture,
before performing the appropriate immunological or PCR
tests [35], [36]. Growth can be observed within 12 to 24 hours
for fast-growing microorganisms, but for slow-growing intracellular microorganisms like MAP it can take from a week up
to several months.Anotherproblem with this technique is that
some microorganisms are difficult to culture in the laboratory,
which limits their detection. Although highly reliable, culture-based PCR can result in the identification of samples as
false-negative, due to the absence of a viable pathogen or the
inability of the pathogen to grow in culture. Therefore, it is
plausible that samples that might be found to be positive by
direct nPCR and hMRS to be identified as negative 12 weeks
after by culture-based nPCR. This is common for low bacterial loads of slow-growing microorganisms that require
highly specialized media and cultural conditions, whose
inadequacy might drastically affect bacterial viability leading
to cell death and DNA degradation [3 7]. These problems in
detection with PCR methods are encountered in the detection
of any intracellular pathogen, as the pathogen has optimized
its adaptation and growth within a host cell. Due to their
sensitivity and minimal sample processing, hMRS are
capable of circumventing PCR's obstacles and achieving
improved clinical diagnosis. Our findings indicate that hMRS
can detect an intracellular pathogen's genomic marker in
biological fluids (i.e. blood) and tissue homogenates within
one hour, where the first 30 minutes are spent on crude DNA
extraction and the remaining time on readout.
Herein, we have also demonstrated that MAP DNA can be
detected in various tissues from Johne's disease animals, as
well as in biopsies and blood from Crohn' s disease patients, at
the epitope and genomic biomarker levels. Furthermore, our
results indicate that hMRS can detect the presence of MAP in
Crohn' s disease patients more reliably than direct or culturedbased nPCR. As a matter of fact, hMRS is a better predictor of

the state of the disease, correlating the clinical state of a
patient with the presence of MAP in blood samples (FIG. 6).
The use ofhMRS could be a powerful new tool in the study of
the mechanism of infection of intracellular pathogens and its
relation to disease state, as well as in elucidating intracellular
pathogens' adaptation strategies [38]. Difficulties in detecting MAP hamper studies aimed at the investigation of the
potential role of MAP in Crohn's disease pathology, as well
as the pathogen's impact on the dairy and beefindustries [39].
Overall, these studies provide evidence for the use ofhybridizing magnetic nanosensors and magnetic relaxation detection to reliably identify the presence of an intracellular pathogen in clinical samples in a fast, cost-effective and highly
sensitive way.
Methods
Preparation ofIS900-Specific hMRS
The IS900-specific hMRS were prepared from propargylated polyacrylic-acid-coated iron oxide nanoparticles, utilizing literature available protocols [11]. Specifically, incorporation of propargyl groups on polyacrylic-acid-coated iron
oxide nanoparticles was achieved via the carbodiimide chemistry, followed by magnetic separation of the nanoparticles,
using an LS25 MACS column (Miltenyi) [11 ]. Subsequently,
the propargyl-functionalized iron oxide nanoparticles were
reacted with an azide-modified oligonucleotide, which is
complementary to a segment ofMAP's IS900 genomic element. Conjugation of the azide-terminated 15-bp oligonucleotide 5'-ATGTGGTTGCTGTGT-3' (SEQ ID NO. 1) was
achieved via "click" chemistry, as previously described [40].
Bn"efly 400 µL propargylated 1·ron oxi"de nanoparti"cles were
'
resuspended in 1,100 µL NaHC03 buffer (0.1 M, pH 8.4). To
this, 200 µL ofl 0 mM TCEP (tris(2-carboxyethyl)phosphane
hydrochloride, Sigma) were added as a reducing agent.
Twenty µL of 6.3 M oligo were diluted in 80 µL NaHC03
buffer (0.1 M, pH 8.4) and added to the nanoparticle solution.
The reaction was initiated with the dropwise addition of 150
µL Cu(I)-TBTA complex (tris(benzyltriazolylmethyl)amine,
10 mM, Sigma), which was previously prepared in DI water
and tbutanol (9[ratio] 1). The reaction was incubated at room
temperature under continuous mixing for 3 hours, followed
by overnight incubation at 4 ° C. under constant mixing. The
resulting IS900 hMRS were dialyzed against DI water using
a 6,000-8,000 MWCO membrane (Spectrum), followed by
magnetic separation with an LS25 MACS column (Miltenyi).
The epitope-sensing MRS were formulated as previously
reported, and the MAP antibody was obtained from Dr. Naser' s lab [12]. Briefly, polyacrylic-acid-coated iron oxide
nanoparticles were conjugated to Protein G via the EDC/NHS
chemistry, in order to have Protein Gas a high-affinity immunoglobulin linker that provides optimal antibody orientation
[12]. The reaction was performed according to the literature,
followed by magnetic separation through a lx-PBS-equilibrated LS25 column and antibody conjugation [12]. The
nanoparticle valency of the antibody-carrying nanoparticles
was assessed through quantification of the nanoparticles' protein content, using published methodologies [ 11]. Size determination of all hMRS was achieved through dynamic light
scattering, using the PDDLS Coo!Batch 40T instrument and
Precision Deconvolve 32 software. Zeta potential measurements were performed on a Malvern zetasizer, while the Rl
and R2 relaxivities were determined after determination of
the nanoparticle's iron content and relaxation studies on a
compact relaxometer (Minispec, Bruker). Determination of
the hMRS oligonucleotide concentration was achieved by
monitoring the absorbance at 260 and 305 nm (background),
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using a Nanodrop 1000 spectrophotometer (Thermo Scientific), as previously described [12]. The hMRS were stored at
4 ° C. until further use.
Bacterial Cultures, Isolates and Homogenized Tissue
Lab strains of MAP and clinical isolates were grown in
12B* BACTEC bottles (Becton Dickinson) as previously
described [21]. Quantification of MAP grown in the
BACTEC bottles was assessed with the BACTEC 460 TB
Analyzer (Becton Dickinson). Heat-inactivation of MAP was
performed by autoclaving the BACTEC bottle for 10 mins.
Proteus vulgaris #8427, Staphylococcus aureus #33862,
Pseudomonas aeruginosa #27853, Enterococcus faecalis,
Escherichia coli #8739, and Serratia marcensis were grown
in culture tubes with nutrient broth, and bacterial growth was
monitored spectrophotometrically. Heat inactivation of these
bacteria was performed by autoclaving the culture tubes for
10 minutes. Upon inactivation, all bacterial stocks were
placed in a Fisher Isotemp freezer (Fisher Scientific), until
further use. Clinical isolates and tissue specimens from animals with Johne's disease were obtained from tissue collections stored in Dr. Naser's laboratory.
Extraction of Pure and Crude Bacterial DNA from Bacterial
Cultures
DNA was extracted from cultured bacteria in a class II
biosafety cabinet, according to literature-available procedures [21]. One mL of bacterial cultures was aseptically
transferred to microcentrifuge tubes, followed by centrifugation at 13,200 rpm. The resulting pellets were resuspended in
120 µL sterile TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0)
and incubated in a dry heat bath at 100° C. Samples without
further processing were used as crude DNA extracts in MRnS
and nPCR studies. In order to obtain pure bacterial DNA,
after heating the samples, we placed them on ice for 15
minutes and then centrifuged them at 12,000 rpm for 10
minutes at 4° C. The supernatants were transferred to Phaselock gel tubes (Eppendorf), which were supplemented with
200 µL of phenol/chloroform/isoamyl alcohol (1: 1:24 v:v,
Acros). The tubes were centrifuged for 5 minutes (12,000
rpm, 4 ° C.), and the supernatants were precipitated using 400
µL 100% ethanol cooled to -20° C. The precipitated DNA
was washed, dried, and finally reconstituted in 50 µL TE
buffer. Pure and crude bacterial DNA was stored at 4 ° C. until
further analysis, whereas spectrophotometric quantification
of DNA content was achieved using a compact spectrophotometer (Nanodrop 1000, Thermo Scientific). Crude and pure
DNA extractions from clinical isolates were similarly performed.
hMRS and Nested PCR Experiments
Serial dilutions of bacterial DNA were prepared in TE
buffer. For the relaxation-mediated experiments, 200 µL of
the nanoparticle suspension (6 µg Fe/mL in 0.1 M phosphate
buffer, 0.1 M NaCl, pH 7.4) were incubated with 1 µL of
bacterial DNA or control (TE buffer). The samples were
heated twice for 3 minutes at 95° C. After this, the samples
were transferred to relaxometer tubes and cooled down at
room temperature, while taking relaxation measurements on
a magnetic relaxometer (Mini spec, Bruker). For the specificity assays using a complementary synthetic target (5'-TCCTTCGGCCATCCAACACAGCAACCACAT-3' (SEQ ID NO.
2), 1 µL of the target (1.1 M) was added to the hMRS mycobacterial samples containing the same DNA concentration
(3.5 ng/µL). Similar DNA concentration was used for the
specificity experiment utilizing other Gram-positive and
Gram-negative bacteria and hMRS (3 µg Fe/mL). For the
sensitivity experiments, serial dilutions of pure and crude
MAP DNA were prepared from pure cultures of MAP grown
in 12B* BACTEC bottles, which had been processed and

quantified as described in the preceding section (DNA extraction methodology). Nested PCR (nPCR) was performed as
previously described [21].
Blood Samples, Extraction of Bacterial DNA from White
Blood Cells and MAP Culturing
Blood samples were collected from healthy individuals
and patients with Crohn's disease atthe University of Florida,
College of Medicine, in accordance to Institutional Review
Board guidelines. The samples were coded and sent to the
University of Central Florida for blind screening via PCR and
hMRS analyses, without knowing in advance the individual's
condition, demographics andMAP's presence (Cohorts 1 and
2). Isolation of white blood cells was achieved via centrifugation at 3,000 rpm for 10 minutes at room temperature, as
previously described [21]. Pure DNA was extracted via phenol/chloroform/isoamyl alcohol precipitation, similar to previously published methodologies. The pure DNA was subjected to direct nested PCR, as described above. Crude DNA
extraction from the isolated white blood cells was achieved
via centrifugation at 13,200 rpm for 2 minutes. The resulting
pellets were resuspended in 120 µL sterile TE buffer (10 mM
Tris, 1 mM EDTA, pH 8.0) and incubated in a dry heat bath at
100° C. for 30 minutes, followed by cooling and centrifugation at 12,000 rpm that provided us with supematants rich in
crude DNA. For bacterial culturing, buffy coat samples were
prepared in sterile phosphate buffered saline as described
before and inoculated on MGIT bottles. The inoculants were
first incubated at 37° C. in a 5% C02 atmosphere for 12
weeks, and then pure DNA extraction was performed as
stated above.
Measurement of Proton Relaxation Times
Spin-spin relaxation times (T2) were measured using a
0.47 T mq20 NMR analyzer (Minispec, Bruker). T2 values
were obtained before and after addition of the sample, and
through the time course of the study. All T2 measurements
were performed using a CPMG pulse-echo train with a 1.5 ms
interpulse spacing (Bruker Corp., Billerica, Mass.). The
change in magnetic resonance signal (ti. T2+) was defined as
the sample's T2 minus the magnetic signal of the corresponding negative control. All experiments and measurements were
carried out in triplicate and data were expressed as
mean±standard error, unless otherwise denoted.
Statistical Analysis
Clinical diagnosis and sample collection was performed at
the College of Medicine, University of Florida, based on
clinical and endoscopic criteria [21]. Samples identified as
IS900-positive by the hMRS method had an average li.T2+
higherthan 1.5 ms, while positive samples bythenestedPCR
method had a unique 298-bp nucleotide sequence. The averages of three independent experiments are reported, unless
otherwise stated. Two-proportion z-test statistics were determined through the SPSS package, with the confidence level
set at 95% (IBM Co.). ROC analysis was performed based on
hMRS determination of the sample's MAP load. This was
achieved through the correlation of the li. T2+ signal to bacterial genome copies, using a crude extracted DNA standard
curve (FIG. 9). For nPCR, the presence of a band corresponding to IS900 was marked as positive (value=!), whereas its
absence was assigned as negative (value=O). The overall ROC
methodology was performed as previously reported in literature [34]. Specifically, the classification variable was the individual's clinical condition (Crohn's disease vs healthy),
whereas the output curve was fitted using logistic regression.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 2
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 15
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; azide modified
oligonucleotide

<400> SEQUENCE, 1
atgtggttgc tgtgt

<210>
<211>
<212>
<213>
<220>
<223>

15

SEQ ID NO 2
LENGTH, 30
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; oligonucleotide

<400> SEQUENCE, 2
30

tccttcggcc atccaacaca gcaaccacat

The invention claimed is:
. 1. A method of detecting a nucleic acid analyte of interest

m a sample, the method comprising:
(a). contacting. nucleic ~cid from a sample with a hybridizmg magnetic relaxat10nnanosensor (hMRS) comprising
a plu.rality of nucl.ei~ acid sequence probes configured to
specifically hybnd1ze to one unique sequence of the
nucleic acid analyte of interest, so that only one hMRS
hybridizes per nucleic acid analyte of interest; and
(b) detecting a change in the magnetic resonance signal
from a hMRS hybridized to a nucleic acid analyte of
interest in the nucleic acid from the sample; thereby
detecting the presence of the nucleic acid analyte of
interest in the sample.
2. The method of claim 1, further comprising the step of
isolating nucleic acid from the sample to obtain isolated
nucleic acid.
.3. The method of claim 2, wherein said contacting nucleic
acid from the sample comprises contacting isolated nucleic
acid with at least one hMRS.
4. The method of claim 1, wherein said sample is any
sample harboring microorganisms from clinical or environmental sources.
5. The method of claim 1, wherein the nucleic acid analyte
of interest is of a microorganism.
6. The method of claim 5, wherein the microorganism is a
strain of bacteria.
7. The method of claim 6, wherein the bacteria is a Mycobacterium, and wherein the Mycobacterium is Mycobacterium avium spp. Paratuberculosis.
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8. The method of claim 5, wherein said nucleic acid analyte
of interest is DNA or RNA sequence of a microorganism.
9. The method of claim 8, wherein said nucleic acid analyte
of interest is IS900 nucleotide sequence specific to MAP.
10. The method of claim 1, wherein said hMRS comprises
a magnetic nanoparticle.
11. The method of claim 10, wherein said magnetic nanoparticle comprises a metal or metal oxide.
12. The method of claim 1, wherein said method can detect
the presence of a nucleic acid analyte of interest within 90
minutes or less.
13. A hybridizing magnetic relaxation nanosensor
(hMRS), comprising a magnetic nanoparticle associated with
a pl~r~lity of nucle.ic acid probes configured to specifically
~ybnd1ze to one umque sequence of a nucleic acid analyte of
mterest, so that only one hMRS hybridizes per nucleic acid
analyte of interest.
14. The hMRS of claim 13, wherein said magnetic nanoparticle comprises a metal or metal oxide.
15. The hMRS of claim 13, wherein said magnetic nanoparticle comprises iron oxide.
16. The hMRS of claim 13, wherein said nucleic acid
analyte of interest is of a microorganism.
17. The hMRS of claim 16, wherein said microorganism is
a strain of bacteria.
18. The hMRS of claim 17, wherein said bacteria is a
Mycobacterium, and wherein said Mycobacterium is Mycobacterium avium spp. Paratuberculosis.
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